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A randomized, double-blind, placebo-controlled cross-over study of adjuvant treatment with remacemide 
hydrochloride was carried out in 17 patients taking sodium valproate (VPA) as monotherapy. Plasma concentration 
profiles of VPA, remacemide, and its active desglycinyl metabolite (ARL12495XX) were determined following 
single (300 mg) and multiple dosing (150 or 300 mg twice daily) of remacemide hydrochloride for 14 days with a 
300-mg final dose. Central nervous system side-effects were more common at the higher dose, which prompted 
dosage reduction to 150 mg twice daily for subsequent patients partway through the study. The mean area under 
the concentration-time curve, peak concentration and pre-dose concentration of VPA were unchanged by 
remacemide hydrochloride in three patients on the higher and in 10 patients on the lower dose of remacemide. The 
pharmacokinetic parameters of remacemide and its active metabolite in the VPA-treated patients were similar to 
those described previously in healthy volunteers. Thus, remacemide hydrochloride does not interfere with the 
pharmacokinetics of VPA and vice versa. 
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INTRODUCTION 
Remacemide hydrochloride (2-amino-N-[l- 
methyl-1,2-diphenylethyll-acetamide monohydro- 
chloride), a novel anticonvulsant, is a non- 
competitive antagonist at N-methyl-D-aSpartate 
(NMDA) receptors’. Metabolism in man involves 
production of an active desglycinyl metabolite2, 
ARL12495XX, which has a longer elimination 
half-life than the parent compound (12-18 s 3-4 
hours)3, and is a potent antagonist at the NMDA 
receptor4. As well as being an anticonvulsant5, 
remacemide hydrochloride could be effective in 
preventing cell damage in the course of ischaemic 
injury6 and in Parkinson’s disease’. Previous 
studies have demonstrated a modest inhibitory 
effect of remacemide on carbamazepine metabol- 
ism, and induction of remacemide metabolism by 
carbamazepine and phenytoinsV9. 
Sodium valproate (VPA) is a first-line anticon- 
vulsant drug, which is effective for generalized 
and partial seizures”. Cognitive effects are less 
severe with VPA than with other antiepileptic 
drugs (AEDs), and its use has been recom- 
mended where psychomotor performance is an 
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important consideration”*‘2. Drug interactions 
are less troublesome with VPA than with 
enzyme-inducing AEDs13, although it has some 
minor enzyme-inhibiting properties14. The pre- 
dilection of the established AEDs to interact with 
other compounds and the need for novel agents 
to be used as adjunctive therapy require early 
assessment of potential pharmacokinetic interac- 
tions, which can obscure interpretation of trial 
results and influence dose selection. This phar- 
macokinetic interaction study with remacemide 
hydrochloride was carried out in patients on VPA 
monotherapy, using a randomized, double-blind, 
placebo-controlled, cross-over design15. 
METHODS 
Patients 
A total of 17 patients were recruited (Table l), 
each taking a regimen of VPA twice daily as 
monotherapy which had been stable for at least 3 
months. All patients had at least one plasma 
measurement of valproic acid within the target 
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Table 1: Demographic characteristics of patients taking sodium valproate twice daily 
Patient Group Sex Age 
bears) 
Seizure 
me(s) 
Valproate 
dose 
b&W 
003* High dose M 54 CPSJ2GTCS 1700 
005 High dose M 57 CPS/2GTCS 1700 
007 High dose F 19 1 GTCS 700 
016 High dose F 19 1GTCS 2000 
002 Low dose M 38 CPS/2GTCS 2000 
004 Low dose M 20 2GTCS 3000 
008 Low dose F 45 SPS/CPS/2GTCS 1200 
cQ9t Low dose M 43 1 GTCS 1000 
010 Low dose M 24 1GTCS 800 
011 Low dose M 37 SPS/CPS/2GTCS 1200 
012 Low dose M 41 SPS/CPS/2GTCS 2500 
018$ Low dose M 19 1GTCS 2600 
022 Low dose F 24 2GTC.S 1000 
023 Low dose F 52 CPS/2GTCS 2400 
024 Low dose M 33 SPS/CPS/2GTCS 3500 
001s Withdrawn F 62 CPS 1800 
006’ Withdrawn M 45 1GTCS 2000 
*Missed last dose of remacemide hydrochloride-omitted from remacemide analysis. 
t Missed last dose of sodium valproate-omitted from VPA analysis. 
$ Received 150 mg last dose of remacemide hydrochloride-omitted from remacemide analysis. 
§ Withdrew due to adverse events on remacemide at 300 mg twice daily. 
q Withdrew due to adverse events on remacemide at 150 mg twice daily. 
SPS, simple partial seizures; CPS, complex partial seizures; IGTCS, idiopathic tonic-clonic seizures; ZGTCS, 
localization-related tonic-clonic seizures. 
range (34.5-695 pmol/l) during that period. 
Eleven of the recruits had partial seizures with or 
without secondary generalization, while six were 
thought to have idiopathic tonic-clonic seizures. 
The study was approved by the West Ethical 
Committee in Glasgow and the Research Ethics 
Committee in Cardiff. Written informed consent 
was obtained from each participant. 
All patients were free from hepatic, renal, or 
haematological disease. They were asked to 
refrain from alcohol and caffeine throughout the 
study. Some patients were on a stable dose of 
other medication, none of which was known to 
interact with VPA or remacemide hydrochloride. 
Patients were required to keep a diary card 
detailing seizure type and frequency and the 
duration and nature of any adverse events 
experienced. Compliance was checked by 
questioning the patients and carrying out a tablet 
count. 
Protocol 
The study had a double-blind, random order, 
placebo-controlled, cross-over design, preceded 
by an open, single-dose treatment phase. Patients 
continued to take VPA twice daily in their usual 
dose throughout. One week following a screening 
visit, each patient received 300 mg remacemide 
hydrochloride. Plasma levels of VPA, re- 
macemide, and ARL12495XX, were measured 0, 
0.5, 1, 1.5,2,4,6, 8, 10, 12,24, and 48 hours after 
dosing. One week later, patients entered the first 
arm of chronic treatment, receiving either re- 
macemide hydrochloride or matched placebo. 
The total treatment period was 14 days (100mg 
twice daily on day 2,200 mg twice daily on day 3 
and 300 mg twice daily thereafter), after which a 
final 300-mg dose of remacemide hydrochloride 
was given on the morning of day 15 to allow 
measurement of steady-state and washout con- 
centrations at the same times after dosing as 
described earlier. Seven days later, the second 
treatment phase commenced and the whole 
procedure was repeated. Morning pre-dose (tro- 
ugh) samples were taken on days 5, 12 and 15 
after initiation of treatment. As 300 mg re- 
macemide hydrochloride twice daily was poorly 
tolerated, the protocol was amended partway 
through the study, and patients subsequently 
received 150 mg twice daily with a 300-mg final 
dose. 
All blood samples were taken into heparinized 
tubes from a cannulated forearm vein, which was 
kept patent between aspirations with normal 
saline. The first 1 ml withdrawn was discarded, 
and the subsequent 15 ml were chillled until 
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centrifugation. All samples were spun at 
3000 rpm for 10 minutes, and the separated 
plasma frozen at -4°C for batch analysis. 
Assays 
Remacemide and ARL12495XX were quantified 
by high performance liquid chromatography 
(HPLC). This was a modification of a previously 
reported methodr6, adjusted to allow automated 
sample preparation and improved selectivity. The 
method involved solid phase extraction of the 
analytes and internal standard followed by 
separation on a reverse phase HPLC system 
utilizing an octadecyl (C-18) HPLC column, an 
acetonitrile based eluent, and ultraviolet detec- 
tion at 210nm. Limits of quantification for the 
two analytes were 10 rig/ml. Only samples from 
the active leg of the double-blind phase were 
analysed for remacemide and ARL12495XX. 
VPA was measured by gas chromatography. 
Plasma samples were acidified prior to extraction 
into chloroform and the organic phase was 
analysed directly by gas chromatography on a 
DB-was analytical column (20m, film thickness 
0.3 pm, 0.18 pm internal diameter) using flame 
ionization. The limit of quantification for this 
method was 50 pmolll of VPA. 
Pharmacokinetics 
The following non-compartmental pharmaco- 
kinetic parameters were computed for VPA for 
all three phases of serial blood sampling: (1) area 
under the concentration-time curve over the 
12-hour dosing interval (A&=) calculated using 
the linear trapezoidal method; (2) peak con- 
centration (C,,,) over the dosing interval; (3) 
pre-dose concentration (C,in) over the dosing 
interval; (4) time to maximum concentrations 
(7’,‘,,X) over the dosing interval; (5) trough 
concentrations 5,‘12, and 15 days after initiation 
of multiple dosing with remacemide hydro- 
chloride or placebo. 
For remacemide and ARL12495XX, the para- 
meters calculated following single and multiple 
dosing were: (1) C,,,; (2) Cmin (multiple dose 
only); (3) T’,,,; (4) A, either extrapolated to 
infinite time (AT) which was calculated from 
A = A, + C,/k, where A, = area under the curve 
up to the last point at which the concentration 
could be quantified, C, = last quantifiable con- 
centration, and k = the terminal phase plasma 
elimination rate constant, or over a 1Zhour 
dosing interval (A&; (5) Terminal elimination 
half-life, (tin) after the single dose and during 
washout of the multiple dose remacemide hydro- 
chloride treatment phase (this was calculated 
from tin = 0.693/k); (6) trough concentrations 5, 
12 and 15 days into remacemide hydrochloride 
treatment-linear superposition of the single 
dose profiles was performed to determine the 
predictability of the multiple-dose profiles 
obtained. 
Statistics 
Statistical comparisons of the pharmacokinetic 
parameters obtained for VPA at the end of the 
multiple-dose phase of the study were compared 
using analysis of variance (ANOVA) with treat- 
ment, period, sequence and-patient as factors. 
Logarithmically transformed data were used for 
analysis of the AsT, C,,, and Cmin comparisons. 
Untransformed data were used for T,,. Analysis 
of the trough concentrations used ANOVA for 
the three concentrations per patient (5,12, and 15 
days after initiation of multiple dosing) with 
factors for treatment, period, sequence, day 
number and patient. Single- and multiple-dose 
phases were compared using a non-parametric 
procedure: the matched pairs Wilcoxon signed 
rank test. a probability of ~5% indicated 
statistical significance. 
RESULTS 
Patients 
Of the 17 patients detailed (Table l), four 
completed the study at the higher dose of 
remacemide hydrochloride. A further 11 compl- 
eted the trial having received 150 mg twice daily 
for at least 9 days. Patients 003,009 and 018 were 
not included in pharmacokinetic analyses (Table 
1). Two patients taking remacemide hydroch- 
loride withdrew due to adverse events (one at 
each dose level). 
VPA pharmacokinetics 
Analysis of VPA pharmacokinetic data from 10 
patients administered single or multiple doses 
(low-dose group) of remacemide hydrochloride 
showed no statistically significant changes over 
placebo (Fig. 1; Table 2). Mean trough con- 
centrations (sd) of VPA 5, 12 and 15 days into 
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Fig. 1: Mean plasma concentrations of valproic acid in 10 
patients with epilepsy following single (300 mg; 0) or 
multiple (150 mg twice daily for 14 days, 300 mg final dose; 
0) dosing with remacemide hydrochloride and multiple 
dose placebo (Cl). 
treatment were similar during the active [522 
(124), 555 (183) and 483 (73) kmol/l respectively] 
and placebo [599 (143), 488 (157) and 491 
(103) pmol/l respectively] treatment phases. 
Remacemide and ARL12495XX 
pharmacokinetics 
Mean plasma profiles obtained after the single 
dose and 14 days of multiple dosing are illustrated 
in Figs 2 (remacemide) and 3 (ARL12495XX) for 
the 10 low-dose patients. Mean pharmacokinetic 
parameters for remacemide and ARL12495XX 
following single and multiple dosing are shown in 
Tables 3 (low dose group) and 4 (high-dose 
group). Based on linear superposition of the 
concentration data, there was good predictability 
of the multiple-dose profiles from the single-dose 
profiles. Moreover, the terminal elimination 
half-lives of remacemide and ARL12495XX were 
similar after single and multiple dosing for 14 
days in both the low- and high-dose groups 
(Tables 3 and 4). After 14 days’ treatment at high 
dose, the AUCs for remacemide and 
ARL12495XX were not significantly different 
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Fig. 2: Mean (&sd) single (0) and multiple (m) dose 
concentrations of remacemide in 10 patients taking sodium 
valproate receiving a single (300 mg) or multiple (150 mg 
twice daily for 14 days, 300 mg final dose) dosing with 
remacemide hydrochloride. 
from those expected from the single-dose AUC 
data (Table 4). Similarly, for the low-dose 
regimen, the multiple-dose exposure was not at 
variance with that expected based on the single- 
dose data and taking account of the dosing 
regimen employed (Table 3). These results 
suggest that linear kinetics prevail, and prove that 
there is no autoinduction of remacemide or 
ARL12495XX metabolism. The serial trough 
concentrations for remacemide and 
ARL12495XX did not demonstrate any trend 
with time in either direction. This is evidence to 
support the hypothesis that steady-state had been 
reached by days and that no autoinduction or 
accumulation occurred thereafter. 
Adverse events 
Of the nine patients started on remacemide 
hydrochloride 300 mg twice daily, three were 
withdrawn from the study. One patient withdrew 
after 14 days of multiple dosing with remacemide 
hydrochloride (300 mg bd) due to central nervous 
system (CNS) side-effects. One patient withdrew 
after 12 days of multiple dosing with remacemide 
Table 2: Mean (sd) pharmacokinetic parameters of sodium valproate after single and multiple doses of remacemide 
hydrochloride and placebo in 10 epileptic patients receiving 300mg final dose after multiple dosing with 150 mg twice daily 
Placebo 
Single dose 
Multiple doses 
A o-12 
(pmol hour/l) 
6493 (1857) 
6704 (2252) 
6451 (1349) 
~Zol,l) $Grs) 
836 (220) 2.7 (1.5) 
776 (256) 4.5 (2.0) 
793 (194) 3.6 (2.0) 
~Gol,l) 
491 (103) 
588(85) 
483 (73) 
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Fig. 3: Mean (*sd) single (0) and multiple (m) dose 
concentrations of ARL12495XX in 10 patients taking sodium 
valproate receiving a single dose (300 mg) or multiple 
(150 mg twice daily for 14 days, 300 mg final dose) dosing 
with remacemide hydrochloride. 
hydrochloride (5 days at 300mg bd, 7 days at 
150 mg bd) due to gastro-intestinal effects. A 
third patient was withdrawn due to intercurrent 
illness after completing multiple dosing with 
remacemide hydrochloride (300 mg bd) but was 
re-entered into the beginning of the double-blind 
phase after an increase in VPA dosage (1500- 
1700mg/day). Two other patients had their 
remacemide hydrochloride dose reduced to 
150 mg twice daily after 4 days, and completed 
the trial satisfactorily at this dose level. The 
side-effects experienced at the higher dose were 
CNS related (dizziness, drowsiness, fatigue) with 
one patient developing dyspepsia, which failed to 
resolve on reducing the remacemide 
hydrochloride dose. 
A similar number of patients reported adverse 
events during dosing with remacemide hydro- 
chloride 150 mg twice daily (seven patients) and 
placebo (five patients). More adverse events were 
reported, however, while patients were receiving 
remacemide hydrochloride treatment (n = 21) 
compared with placebo (n = 8), particularly CNS 
side-effects (active treatment-10 events; 
placebo-l event). Gastrointestinal symptoms 
were reported by two patients during active 
treatment, with none occurring on placebo. 
DISCUSSION 
Remacemide is eliminated almost exclusively by 
metabolic transformation. Apart from the active 
desglycinyl metabolite, ARL12495XX, which is 
formed by ubiquitous aminopeptidase enzymes, 
there are a number of oxidative biotransforma- 
tion products. In addition, remacemide un- 
dergoes direct glucuronidation to form a car- 
bamoyl glucuronide metabolite, a major pathway 
in man3. This interaction study used a placebo- 
controlled design in order to investigate the 
potential interaction between remacemide hydro- 
chloride and VPA. Following multiple dosing, no 
significant effect was seen on VPA metabolism. 
This study also offered the opportunity to 
provide a pharmacokinetic profile of remacemide 
and ARL12495XX in non-enzyme induced epi- 
leptic patients. For both compounds, the 
multiple-dose profile was consistent with that 
predicted from the single dose, indicative of 
linear disposition and the absence of autoinduc- 
tion of metabolism. Moreover, the mean terminal 
elimination half-life of both remacemide and 
ARL12495XX in the VPA-treated patients after 
single and chronic dosing were similar to those 
found previously in untreated volunteers3. This 
was in contradistinction to the lower half-lives 
previously reported in enzyme-induced 
carbamazepine-* and phenytoin-treated’ patients. 
The most common adverse events with re- 
macemide hydrochloride tend to be dizziness and 
gastrointestinal upse?. In this study, a higher 
number of adverse events were reported during 
the active treatment phase than with placebo. In 
particular, a number of patients were unable to 
tolerate the higher dose of remacemide hydroch- 
loride due to CNS-related side-effects. These 
Table 3: Mean (sd) pharmacokinetic parameters of remacemide and AFlL12495XX in 10 valproate-treated patients following 
single (300 mg) and multiple (150 mg twice daily for 14 days, 300 mg final dose) dosing with remacemide hydrochloride 
T max 
(hours) 
A* 
(ng hour/ml) 
h 
(hours) 
Single dose 
Remacemide 817 (257) NA 1.3 (0.8) 
ARL12495XX 77 (25) NA 5.2 (2.7) 
Multiple doses 
Remacemide 706 (380) 46.7 (25) 1.2 (0.3) 
ARL12495XX 104 (41) 46.4 (14) 2.8 (1.2) 
*A, for single dose profiles, A,, for multiple dose profiles. NA, not applicable. 
3465 (880) 4.2 (0.7) 
1868 (643) 15.5 (3.8) 
2644 (1348) 4.2 (0.9) 
925 (364) 15.0 (5.6) 
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Table.4’: :Mean (sd)pharmacokinetic parameters of remacemide and ARL12495XX in three valproate-treated patients following 
acute,and chronic dosing with 300 mgtwice daily 
Gli, A* ‘l/z 
b-s/ml) (ng hour/ml) (hours) 
Single dose 
Remacemide 934 (408) NA 1.5 (0.5) 
ARL12495xx 123 (45) NA 3.5 (2.3) 
Multiple doses 
Remacemide 803 (242) 61.8 (50) 1.0 (0.5) 
ARL12495xx 159 (39) 85.4 (16) 1.8 (0.3) 
* %. for single dose profiles, A,, for multiple dose protiles. NA, not applicable. 
3391 (811) 4.3 (2.1) 
1840 (527) 13.8 (5.9) 
2791 (572) 3.5 (0.5) 
1351 (155) 10.3 (2.4) 
adverse events were not a result of a 
phmacokinetic interaction between the two 
drugs. It is possibly a consequence of the fast 
titration schedule used in this study. 
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